Recent advances in targeted therapies for colorectal cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Advances in colorectal cancer molecular biology and genetics have identified targets like epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and other endothelial receptors.
• These targets form the basis for novel therapeutic strategies in colorectal cancer treatment.

Purpose of the Study:

• To review major therapeutic advances in colorectal cancer, focusing on targeted therapies.
• To examine the preclinical evidence supporting the combination of targeted therapies with conventional treatments.
• To critically assess methods for identifying patients who will respond to targeted therapies.

Main Methods:

• Review of preclinical data and primary clinical trial results from peer-reviewed journals.
• Evaluation of the relevance and inclusion of scientific data.

Main Results:

• Cetuximab and bevacizumab demonstrate significant benefits, improving response rates and patient survival in colorectal cancer.
• Current research highlights the need for further investigation into optimal combinations of targeted therapies and conventional chemotherapy.

Conclusions:

• Targeted therapies offer new benefits but raise questions about optimal drug combinations and patient selection.
• The high cost of targeted treatments necessitates the development of tools to identify the right drug for the right patient.
• Predictive tools for assessing the efficacy of targeted colorectal cancer treatments are still required.